Skip to search formSkip to main contentSkip to account menu

BMS 207940

Known as: BMS-207940, BMS207940 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Synthesis and In Vivo Evaluation of Novel PET Radioligands for Imaging the Endothelin-A Receptor
The endothelin subtype-A (ETA) receptor is a member of a family of G-protein–coupled receptors that plays a central role in… 
2005
2005
Characterization of the in vitro atropisomeric interconversion rates of an endothelin A antagonist by enantioselective liquid chromatography.
2004
2004
Simulation of the Impact of Atropisomer Interconversion on Plasma Exposure of Atropisomers of an Endothelin Receptor Antagonist
BMS‐207940, a potent endothelin receptor antagonist, exists as rapidly interconverting atropisomers. The plasma interconversion… 
Review
2002
Review
2002
BMS-193884 and BMS-207940 Bristol-Myers Squibb.
Bristol-Myers Squibb is developing BMS-193884, an oral endothelin antagonist, for the potential treatment of congestive heart… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)